Tellos Pharmaceuticals
This article was originally published in The Gray Sheet
Executive Summary
Premarket approval application for the company's Argidene gel for the treatment of diabetic foot ulcers accepted for filing by FDA. According to the San Diego-based company, clinical trial data for the PMA submission showed four times as many ulcers "completely healed" in response to treatment with Argidene as compared with those in a control group; healing rates were also "significantly more rapid"